Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

NCT02752685 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02752685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02752685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
December 31, 2025
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer